CompletedPhase 3NCT01502241

Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly

Studying Anaplastic astrocytoma

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Heidelberg University
Principal Investigator: Michael Weller
University of Zurich
Intervention: Temozolomide(drug)
Enrollment: 412 enrolled
Eligibility: 65 years · All sexes
Timeline: 2005 – 2011

Study locations (23)

University of Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
University of Frankfurt, Frankfurt am Main, Hesse, Germany
Charite Berlin, Berlin, Germany
University of Bochum, Bochum, Germany
University of Bonn, Bonn, Germany
University of Dresden, Dresden, Germany
University of Düsseldorf, Düsseldorf, Germany
University of Erlangen, Erlangen, Germany
University of Essen, Essen, Germany
University of Freiburg, Freiburg im Breisgau, Germany
University of Hamburg, Hamburg, Germany
University of Hannover II, Hanover, Germany
University of Hannover, Hanover, Germany
University of Homburg, Homburg, Germany
University of Kiel, Kiel, Germany
+8 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01502241 on ClinicalTrials.gov

Other trials for Anaplastic astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic astrocytoma →

← Back to all trials